# A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

> **NCT05153434** · PHASE2 · COMPLETED · sponsor: **Aardvark Therapeutics, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** ARD-101

## Key facts

- **NCT ID:** NCT05153434
- **Lead sponsor:** Aardvark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-27
- **Primary completion:** 2024-09-24
- **Final completion:** 2024-09-24
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153434, "A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05153434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*